Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an announcement.
Hansoh Pharmaceutical Group Company Limited announced that its innovative drug Ameile (Aumolertinib Mesilate Tablets) has received drug registration approval from the National Medical Products Administration of China for a third indication. This approval is for treating patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) with specific EGFR mutations. This development strengthens Hansoh’s position in the pharmaceutical industry, particularly in the NSCLC treatment market, and highlights its commitment to advancing cancer therapies.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative drugs. The company specializes in treatments for non-small cell lung cancer (NSCLC) and has developed Ameile, a third-generation EGFR-TKI drug, which is wholly developed in China.
YTD Price Performance: 11.34%
Average Trading Volume: 5,864,445
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$114.2B
For detailed information about 3692 stock, go to TipRanks’ Stock Analysis page.